Value of Joint Programs Underestimated

[Excerpt] I am happy to comment on a provocative monograph that raises important issues for union policies and strategies. The authors make two main points: 1. Unions should be proactive in developing worker participation programs in industry and should push them beyond the shopfloor into strategic economic and technological issues. 2. As far as possible, worker participation programs should be controlled by the union. Union leaders should firmly reject programs jointly controlled by union and management. I agree with the first point and disagree with the second. I also question what I see as a bias in selecting case examples to support the Banks-Metzgar thesis. If authors are free to choose any cases to support their arguments, they can prove almost anything

7. The 1970s

From View from the Dean’s Office by Robert McKersie. “I had been on the job just a week when Keith Kennedy, vice provost, called and said we needed to make a trip to Albany to meet the chancellor of SUNY, Ernest Boyer. This was late August 1971. After a few pleasantries, it became clear that this was not just the courtesy call of a new dean reporting in to the top leader of the state university. Chancellor Boyer went right to the point: a new Labor College was going to open on the premises of Local 3 IBEW’s training facility on Lexington Avenue in Manhattan, and the ILR School had to be there as a partner. It was not clear what unit of SUNY would take over the Labor College, but it was clear that given its broad mandate for labor education, the ILR School was going to play a key role.” Includes: View from the Dean’s Office; From Eric Himself; Another Perspective; Labor College Graduation: VanArsdale’s Dream Fulfilled; The View of a Visiting Faculty Member; Another Perspective; and The Student’s View

3. Launching the New Enterprise

As the academic year of 1945-46 approached, the intensity of activity in preparation for actually opening the school in the fall term became overwhelming. Incredible though it may seem, Ives and Day were able in a period of a few weeks to assemble the nucleus of a faculty, several of whom formed a continuing source of counsel and advice both during the school’s formative years and thereafter. Includes: The First Dean and the School’s Dedication; A Participant’s View of the Early Years; Ives Moves On; Several Views of Martin P. Catherwood; The Founders

Hearing aid validation

Validation provides quality assurance that a hearing aid wearer’s needs are being met—that the solution meets not only their technical requirements (i.e., verification) but also their requirements for everyday communication. In the past 50 years, there have been repeated calls for better measures of hearing aid performance, with a general shift in validation toward the self-report of hearing, communication, and well-being through questionnaires. This chapter looks at these measures, examining the domains of hearing aid validation and how despite the growth in number of questions—a total of more than 1,000 questions on hearing aids—the domains have evolved only slightly. The chapter then considers the ways in which a fundamental domain, “benefit,” is calculated. A large data set shows how different forms of benefit can lead to different systematic interpretations. While most objective measures for hearing aids are by definition verifications, the chapter discusses those objective measurements that approach validation by attempting to mimic aspects of everyday communication. The issues raised by these myriad forms of validation suggest that a viable measure of hearing aid benefit must incorporate measures of expectations and burdens for listener-specific conditions

Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.

Hypophosphatasia (HPP) is a rare, inherited, systemic, metabolic disorder caused by autosomal recessive mutations or a single dominant-negative mutation in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). The disease is associated with a broad range of signs, symptoms, and complications, including impaired skeletal mineralization, altered calcium and phosphate metabolism, recurrent fractures, pain, respiratory problems, impaired growth and mobility, premature tooth loss, developmental delay, and seizures. Asfotase alfa is a human, recombinant enzyme replacement therapy that is approved in many countries for the treatment of patients with HPP. To address the unmet need for guidance in the monitoring of patients receiving asfotase alfa, an international panel of physicians with experience in diagnosing and managing HPP convened in May 2016 to discuss treatment monitoring parameters. The panel discussions focused on recommendations for assessing and monitoring patients after the decision to treat with asfotase alfa had been made and did not include recommendations for whom to treat. Based on the consensus of panel members, this review provides guidance on the monitoring of patients with HPP during treatment with asfotase alfa, including recommendations for laboratory, efficacy, and safety assessments and the frequency with which these should be performed during the course of treatment. Recommended assessments are based on patient age and include regular monitoring of biochemistry, skeletal radiographs, respiratory function, growth, pain, mobility and motor function, and quality of life. Because of the systemic presentation of HPP, a coordinated, multidisciplinary, team-based, patient-focused approach is recommended in the management of patients receiving asfotase alfa. Monitoring of efficacy and safety outcomes must be tailored to the individual patient, depending on medical history, clinical manifestations, availability of resources in the clinical setting, and the clinician's professional judgment

Pilot study of sources and concentrations of size-resolved airborne particles in a neonatal intensive care unit

Infants in neonatal intensive care units (NICUs) are vulnerable to environmental stressors. Few studies have reported on airborne particles in the NICU environment. During a four-day pilot study in a private-style NICU, we measured size-resolved particle number (PN) concentrations with 1-min resolution. The investigation included simultaneous sampling in an unoccupied baby room and in an incubator of an otherwise normally functioning NICU. Background submicron (0.3-1 µm) particle levels in the room were 3-4 orders of magnitude lower than outdoors, owing to high-efficiency particulate filtration of supply air. Airborne supermicron particles were detected in the room; their presence was attributed primarily to emissions from occupant movements. The fraction of in-room PN detected within an infant incubator ranged from 0.2 for particles >10 µm to 0.6 for particles with diameter 0.3-0.5 µm. The incubator humidifier was a strong additional source of particles smaller than 5 µm. Activities by researchers, designed to simulate caregiver visits, were associated with elevated particle concentrations across all measured size ranges, and were particularly discernible among larger particles. Concentrations increased with the number of occupants and with the duration and vigor of activities. The highest levels were observed when fabrics were handled. Against the low background in this environment, even small occupancy-associated perturbations – such as from a brief entry – were discernible. Measurements from a second NICU in a different US region were found to be broadly similar. A notable difference was higher submicron particle levels in the second NICU, attributed to elevated outdoor pollution

Amenability of groups and GG-sets

This text surveys classical and recent results in the field of amenability of groups, from a combinatorial standpoint. It has served as the support of courses at the University of G\"ottingen and the \'Ecole Normale Sup\'erieure. The goals of the text are (1) to be as self-contained as possible, so as to serve as a good introduction for newcomers to the field; (2) to stress the use of combinatorial tools, in collaboration with functional analysis, probability etc., with discrete groups in focus; (3) to consider from the beginning the more general notion of amenable actions; (4) to describe recent classes of examples, and in particular groups acting on Cantor sets and topological full groups

Clinical Trials in Head Injury

Traumatic brain injury (TBI) remains a major public health problem globally. In the United States the incidence of closed head injuries admitted to hospitals is conservatively estimated to be 200 per 100,000 population, and the incidence of penetrating head injury is estimated to be 12 per 100,000, the highest of any developed country in the world. This yields an approximate number of 500,000 new cases each year, a sizeable proportion of which demonstrate signficant long-term disabilities. Unfortunately, there is a paucity of proven therapies for this disease. For a variety of reasons, clinical trials for this condition have been difficult to design and perform. Despite promising pre-clinical data, most of the trials that have been performed in recent years have failed to demonstrate any significant improvement in outcomes. The reasons for these failures have not always been apparent and any insights gained were not always shared. It was therefore feared that we were running the risk of repeating our mistakes. Recognizing the importance of TBI, the National Institute of Neurological Disorders and Stroke (NINDS) sponsored a workshop that brought together experts from clinical, research, and pharmaceutical backgrounds. This workshop proved to be very informative and yielded many insights into previous and future TBI trials. This paper is an attempt to summarize the key points made at the workshop. It is hoped that these lessons will enhance the planning and design of future efforts in this important field of research.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/63185/1/089771502753754037.pd